CHMP recommends Galvus plus insulin and Eucras triple therapy for Type 2 Diabetes

Novartis announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued two positive opinions for new indications for the use of Galvus (vildagliptin) and Eucras (vildagliptin and metformin) in combination with other treatments for Type 2 Diabetes patients. The first positive opinion was for Galvus in combination with insulin, with or without metformin, for patients with Type 2 Diabetes when diet, exercise and a stable dose of insulin do not result in glycemic control. The second positive opinion was for Eucras in triple combination with metformin and a sulphonylurea for the treatment of Type 2 Diabetes when diet and exercise plus dual therapy with these two agents do not provide adequate glycemic control.